Skyepharma has a number of inhalation projects in its development pipeline. Some are our own developments whilst others are being developed with our partners.

Product PlatformCountryPrimary IndicationLicensee / PartnerFeasibilityPh
I
Ph
II
Ph
III
Filed
SKP-2075GlobalCOPD / Smoking Asthma (ACOS)Available
SKP-2076GlobalAsthmaUnder option to Mundipharma
flutiform®Rest of WorldAsthmaMundipharma*
flutiform®Latin AmericaAsthmaMundipharma*
flutiform®Europe and ChinaCOPDMundipharma
flutiform®U.S.AsthmaAvailable
flutiform®CanadaAsthmaAvailable

* Mundipharma has filed marketing authorisation applications in some Rest of World markets
Cross Complete response letter received January 2010 and additional studies are required

White Dot Partial

Triangle Planned 2016/7


Contact us to find out how we can help with your inhalation development.

Disclaimer Masterpage